Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Vera Therapeutics Inc (NASDAQ: VERA) closed at $24.19 down -4.08% from its previous closing price of $25.22. In other words, the price has decreased by -$4.08 from its previous closing price. On the day, 1.29 million shares were traded. VERA stock price reached its highest trading level at $25.41 during the session, while it also had its lowest trading level at $23.86.
Ratios:
For a deeper understanding of Vera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.09 and its Current Ratio is at 12.09. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, BofA Securities on October 16, 2025, initiated with a Buy rating and assigned the stock a target price of $48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 23 ’25 when ENRIGHT PATRICK G bought 209,393 shares for $20.87 per share. The transaction valued at 4,369,676 led to the insider holds 3,569,522 shares of the business.
ENRIGHT PATRICK G bought 40,607 shares of VERA for $907,635 on Jun 24 ’25. The Director now owns 3,596,593 shares after completing the transaction at $22.35 per share. On Feb 21 ’25, another insider, Fordyce Marshall, who serves as the PRESIDENT AND CEO of the company, sold 10,613 shares for $27.89 each. As a result, the insider received 296,032 and left with 213,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERA now has a Market Capitalization of 1546419840 and an Enterprise Value of 1126246912.
Stock Price History:
The Beta on a monthly basis for VERA is 1.25, which has changed by -0.5029793 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -11.50%, while the 200-Day Moving Average is calculated to be -5.07%.
Shares Statistics:
For the past three months, VERA has traded an average of 1.58M shares per day and 1650290 over the past ten days. A total of 63.89M shares are outstanding, with a floating share count of 48.61M. Insiders hold about 23.96% of the company’s shares, while institutions hold 89.94% stake in the company. Shares short for VERA as of 1760486400 were 9755730 with a Short Ratio of 6.17, compared to 1757894400 on 9358966. Therefore, it implies a Short% of Shares Outstanding of 9755730 and a Short% of Float of 17.61.
Earnings Estimates
Vera Therapeutics Inc (VERA) is currently under the scrutiny of 5.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.14, with high estimates of -$0.95 and low estimates of -$1.28.
Analysts are recommending an EPS of between -$4.4 and -$4.8 for the fiscal current year, implying an average EPS of -$4.6. EPS for the following year is -$4.47, with 8.0 analysts recommending between -$3.1 and -$5.52.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $38.46M in the next fiscal year. The high estimate is $63.54M and the low estimate is $2.57M.
